• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Hypertension: St. Jude Medical lands EU approval for next-gen EnligHTN

Hypertension: St. Jude Medical lands EU approval for next-gen EnligHTN

September 3, 2013 By Ingrid Mezo

St. Jude Medical gets European green light for 2nd generation renal denervation system

St. Jude Medical (NYSE:STJ) won CE Mark approval in the European Union for its next-generation EnligHTN renal denervation system, which the company says can cut ablation time by as much as 80%.

The device, indicted for use in patients with drug-resistant, uncontrolled hypertension, is slated for launch during the 2013 European Society of Cardiology meeting from August 31 to September 3 where EnligHTN will be on display, the St. Paul, Minn.-based medical device said in a press release.

The EnligHTN device applies radiofrequency energy to create tiny scars along nerves that control blood pressure. A multi-electrode catheter and newer energy-generator deliver simultaneous ablations, reducing total ablation time from around 24 minutes to 4 minutes, St. Jude said.

The 1st-generation EnligHTN Renal Denervation System gained a European CE Mark in 2012 and was launched in several markets, but the EnligHTN systems are not yet approved for use in the U.S.

"The next generation EnligHTN system offers physicians our proven multi-electrode catheter with a new intuitive, faster generator that quickly and effectively delivers consistent ablations with a significant reduction in procedure time," cardiovascular and ablation technologies president Frank Callaghan said in prepared remarks. "These advancements deliver on our strategy to bring new innovations to a developing market to provide options for patients who currently do not have an adequate treatment for their uncontrolled drug-resistant hypertension."

The World Health Organization estimates that there are more than 100 million people worldwide with treatment resistant hypertension, for whom at least 3 high blood pressure drugs have failed. Global health care costs directly related to hypertension are estimated at almost $508.51 billion (€385 billion) each year.

The use of catheter-based renal denervation for patients with drug-resistant hypertension was recently recommended in guidelines issued by the European Society of Cardiology and the European Assn. of Percutaneous Cardiovascular Interventions, St. Jude noted.

More EnligHTN trials in the works

St. Jude earlier this year kicked off a U.S. trial for EnligHTN and the company is conducting a total of 5 renal denervation studies including the EnligHTNment trial, the 1st large-scale trial evaluating the long-term effects of renal denervation, the company said. 

The EnligHTNment study will evaluate whether the therapy reduces the risk of heart attack, stroke, heart failure requiring hospitalization, and cardiovascular death in patients with uncontrolled hypertension.

The next-generation EnligHTN system is under evaluation in the EnligHTN III study, an international, non-randomized clinical trial that will enroll up to 50 patients in Australia and New Zealand. EnligHTN III aims to expand on data from the 1st-generation EnligHTN trial, which showed that patients with drug-resistant hypertension had a safe, rapid and sustained drop in blood pressure, according to St. Jude Medical.

Filed Under: News Well, Regulatory/Compliance Tagged With: Ablation, CE Mark, Clinical Trials, Hypertension, Minnesota, stjudemedical

More recent news

  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy